The viability of using EGFR-TKI in conjunction with other NSCLC treatments, such as radiation, cytotoxic chemotherapies, targeted therapies, and new immunotherapies, has been the subject of numerous clinical investigations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.